Global Human Rotavirus Vaccine Market Analysis Report 2019-2026 | Competitive Players-Merck & Co., Inc., Bharat Biotech, GlaxoSmithKline plc among others

Global human rotavirus vaccine market is expected to register a healthy CAGR of 11.7% in the forecast period of 2019-2026

Global human rotavirus vaccine market is expected to register a healthy CAGR of 11.7% in the forecast period of 2019-2026.

The market parameters of Human Rotavirus Vaccine report are of immense use to analyse market status, market share, growth rate, future trends, market drivers, opportunities, challenges, risks, entry barriers, sales channels, and distributors. Key data and information used while forming this report has been gathered from the consistent sources that range from journals, websites, research papers, case studies, and magazines. This market research report is a careful investigation of current scenario of the market and future estimations which deals with several market dynamics. Pharmaceutical industry can achieve great benefits with Human Rotavirus Vaccine market research report which brings market and competitive landscape clearly into the focus and assist to make better decisions.

Download  Sample Copy of Report

Some of the major players operating in global human rotavirus vaccine market are Merck & Co., Inc., Bharat Biotech, GlaxoSmithKline plc among others.

Market Segmentation: Global Human Rotavirus Vaccine Market

By type the global human rotavirus vaccine market is segmented into Rotarix, Rotarix, Rotavac, Rotavin-M1, Lanzhou Lamb and others.

On the basis of end user the global human rotavirus vaccine market is segmented into hospitals, clinics, academic & research lab.

On the basis of distribution channel the global human rotavirus vaccine market is segmented into hospital pharmacies and drug stores.

On the basis of geography, global human rotavirus vaccine market report covers data points for 28 countries across multiple geographies such as North America & South America, Europe, Asia-Pacific, and Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa, and Brazil among others. In 2017, North America is expected to dominate the market.

Inquire Regarding This Report

Major Market Drivers and Restraints:

Growing awareness of vaccines among patients

Rising number of immunity-compromised individuals

Side effects and immune reaction

Strict regulatory requirements

High costs of vaccines


Increasing prevalence of rotavirus diseases:

Rotavirus has been the leading cause of severe diarrhea in infants and children. Rotaviruses are responsible to affect the populations in all socioeconomic groups and it is prevalent in industrialized as well as in developing countries. The rotavirus infection is highly transmittable and the people who are around the infected people are at high risk of infection.

The World Health organization (WHO), in 2016 estimated that globally 2,15,000 (1,97,000-2,33,000) child deaths occurred during 2013 due to rotavirus infection compared to 5,28,000 (4,65,000-5,91,000) in 2000. It also reported that 22.0% of deaths under 5 years of age occurred in India. Accompanied by India, Nigeria, Pakistan and the Democratic Republic of the Congo accounted approximately 49.0% of all deaths under the age of 5 in 2013.

Access Complete Report @

Government Initiative:

As rotavirus infection has been the most common cause of severe diarrhea, many national authorities has taken initiatives to launch rotavirus vaccines in the market. India is one of the most affected countries by rotavirus. It is been studied that in India, rotavirus diarrhea causes 110,000 deaths amongst the annual over 450,000 deaths worldwide.

In India, in March 2015 Hon’ble Prime Minister Narendra Modi launched rotavirus vaccine Rotavac, developed by Hyderabad-based Bharat Biotech. In 2017, the Serum Institute of India Pvt. Ltd. revealed the result of clinical trial Phase 3 efficacy study of rotavirus vaccine BRV-PV, ROTASIIL. The study has showed that vaccine is safe, well tolerated, and to provide significant efficacy against severe rotavirus gastroenteritis. And therefore, Indian Government orders the vaccine for use in Universal Immunization Program.

Browse Related Reports:      

Global Pediatric Vaccine Market, By Product (pediatric vaccines, CNS drugs, pediatric hormones, allergy & respiratory drugs and anti-infective drugs); By Technology (dendritic cells vaccines, live attenuated vaccines, synthetic vaccines, toxoid vaccines, inactivated vaccines, conjugate vaccines, recombinant vector vaccines and subunit vaccines); By Disease (Infectious disease, cancer and allergy); End-Users (Pediatric, Adult); Geography (North America, Europe, Asia-Pacific, Europe, South America, Middle East and Africa)- Industry Trends and Forecast to 2024

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.


Data Bridge Market Research

Tel: +1-888-387-2818


Back to top button